Trade Aligos Therapeutics, Inc. - ALGS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.3084 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 31.5658 |
| Open | 31.1058 |
| 1-Year Change | 4324.72% |
| Day's Range | 31.1058 - 33.9658 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 33.9658 | 2.0000 | 6.26% | 31.9658 | 34.2058 | 31.1058 |
| Jan 16, 2025 | 31.5658 | -0.4000 | -1.25% | 31.9658 | 32.0658 | 30.1858 |
| Jan 15, 2025 | 31.6858 | 0.9700 | 3.16% | 30.7158 | 33.1358 | 30.6658 |
| Jan 14, 2025 | 29.8958 | -5.0700 | -14.50% | 34.9658 | 34.9658 | 29.3158 |
| Jan 13, 2025 | 34.2858 | 2.2700 | 7.09% | 32.0158 | 34.8658 | 30.8758 |
| Jan 10, 2025 | 33.4458 | -2.5300 | -7.03% | 35.9758 | 37.1658 | 28.0158 |
| Jan 8, 2025 | 38.1258 | -1.0900 | -2.78% | 39.2158 | 40.3958 | 36.2458 |
| Jan 7, 2025 | 40.6758 | -5.4400 | -11.80% | 46.1158 | 46.1158 | 40.4158 |
| Jan 6, 2025 | 45.5858 | 1.4200 | 3.22% | 44.1658 | 46.6458 | 42.4658 |
| Jan 3, 2025 | 43.3158 | 3.3300 | 8.33% | 39.9858 | 44.1858 | 39.9658 |
| Jan 2, 2025 | 39.7758 | -0.6400 | -1.58% | 40.4158 | 42.0158 | 37.9658 |
| Dec 31, 2024 | 39.6658 | -0.8000 | -1.98% | 40.4658 | 40.6658 | 34.2858 |
| Dec 30, 2024 | 40.2258 | 0.7600 | 1.93% | 39.4658 | 40.8458 | 36.9658 |
| Dec 27, 2024 | 41.1158 | -1.2800 | -3.02% | 42.3958 | 43.7858 | 39.4658 |
| Dec 26, 2024 | 43.3158 | 3.4700 | 8.71% | 39.8458 | 43.8558 | 38.0958 |
| Dec 24, 2024 | 39.1158 | -0.3500 | -0.89% | 39.4658 | 42.1758 | 38.8658 |
| Dec 23, 2024 | 38.7858 | -3.2800 | -7.80% | 42.0658 | 42.0758 | 38.4958 |
| Dec 20, 2024 | 39.7158 | 3.1400 | 8.58% | 36.5758 | 41.4158 | 35.9658 |
| Dec 19, 2024 | 38.0658 | 3.1300 | 8.96% | 34.9358 | 39.0858 | 34.3158 |
| Dec 18, 2024 | 32.9658 | -2.5000 | -7.05% | 35.4658 | 38.3758 | 31.0758 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aligos Therapeutics, Inc. Company profile
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com